Kidney Disease

 
FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
May 03, 2021

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
December 08, 2020

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
December 03, 2020

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.